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Available online 26 May 2007Since adenosine A2A receptor (A2ARs) blockade protects against
noxious brain insults involving apoptosis, we directly tested if A2AR
blockade prevents apoptosis induced by staurosporine (STS). Ex-
posure of rat hippocampal neurons to STS (30 nM, 24 h) decreased
neuronal viability while increasing the number apoptotic-like neurons
and de-localizing mitochondria and cytochrome c immunoreactivities.
This was prevented by the selective A2AR antagonists, SCH58261 and
ZM241385 (50 nM). Shorter incubation periods (6 h) with STS caused
no neuronal loss but decreased synaptophysin and MAP-2 immunor-
eactivities, which was prevented by SCH58261. Furthermore, STS
(100 nM) decreased MTTreduction and increased caspase-3 activity in
rat hippocampal nerve terminals, which was prevented by SCH58261.
These results show that A2AR blockade inhibits STS-induced
apoptotic-like neuronal cell death. This begins with an apoptotic-like
synaptotoxicity, which later evolved into an overt neurotoxicity, and
A2ARs effectively control this initial synaptotoxicity, in agreement with
their predominant synaptic localization in the hippocampus.
© 2007 Published by Elsevier Inc.
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Adenosine is a ubiquitous neuromodulator in the brain, which
mainly acts through two metabotropic adenosine receptors with
opposite functions, namely the predominant inhibitory A1 and
facilitatory A2A receptors (A2ARs) (Fredholm et al., 2005).
Adenosine plays an important role in controlling neuronal survival
in noxious brain conditions in accordance with its pivotal⁎ Corresponding author.
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Cunha, 2001). Thus, the levels of adenosine rapidly rise as a
result of increased workload or decreased metabolic competence of
brain tissue (Latini and Pedata, 2001) and the extracellular levels of
adenosine produce biphasic effects in the control of neuronal
viability in the adult brain: the initial activation of A1Rs acts as a
hurl increasing the threshold required for brain damage (de
Mendonça et al., 2000); the over-activation of A1Rs leads to their
desensitization and adenosine then mainly acts through A2ARs
which mainly seem to contribute for the aggravation of brain
damage in chronic noxious brain conditions in adults (reviewed in
Cunha, 2005). Accordingly, the blockade of A2ARs affords
protection against different brain insults (Cunha, 2005; Xu et al.,
2005), namely in chronic neurodegenerative conditions such as
Parkinson’s, Alzheimer’s, or Huntington’s disease, which involve
apoptotic neuronal features (Rego and Oliveira, 2003; Vila and
Przedborski, 2003). The mechanism underlying this neuroprotec-
tion remains unraveled, but the ability of A2AR antagonists to
directly protect cultured neurons against noxious insults that trigger
neuronal damage featuring apoptotic-like characteristics (Dall’Igna
et al., 2003; Mojsilovic-Petrovic et al., 2006) prompts the
hypothesis that A2ARs might directly control apoptosis in neurons.
We now directly tackled this question by testing if the blockade of
A2ARs might prevent neuronal damage caused by the prototypic
apoptotic inducer, staurosporine (e.g. Bertrand et al., 1994; Koh
et al., 1995).
Materials and methods
Primary cultures of hippocampal neurons
Hippocampal neurons were cultured from 17- to 19-day-old
Wistar rat embryos, handled according to European guidelines (86/
609/EEC), as previously described (Rebola et al., 2005a,b), and
plated on poly-D-lysine-coated 16-mm-diameter coverslips or 6-well
dishes at densities of 5×104/coverslip (viability and immunocy-
tochemistry assays) or 1×106/well (Western blot analysis). Neurons
were grown at 37 °C in a 5% CO2 humidified atmosphere in
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glutamine (0.5 mM) and gentamicin (0.12 mg/ml).
Staurosporine (STS)-induced neuronal damage was evaluated
after culturing the neurons for 7 days by directly adding STS
(30 nM) to the medium followed by incubation for periods
between 6 and 24 h. To test the ability of SCH58261 or ZM241385
to modify the effects of STS, they were added 15 min before the
addition of STS onwards.
Viability assays
Viability assays were performed by double labelling (3-min
incubation) with the fluorescent probes Syto-13 (4 μM) and
propidium iodide (PI, 4 μg/ml) (Molecular Probes, Leiden, The
Netherlands) followed by fluorescence microscopy cell counting.
As previously described (Rebola et al., 2005b), viable neurons
present nuclei homogenously labelled with Syto-13 (green fluor-
escent nuclei), whereas apoptotic neurons show condensed and
fragmented nuclei labelled with Syto-13 (primary apoptosis) or with
Syto-13 plus PI (secondary apoptosis) and necrotic neurons present
intact nuclei labelled with PI (red fluorescent nuclei). In parallel, the
nuclear morphology of hippocampal neurons was analyzed by
fluorescence microscopy using Hoechst 33342 (2 μg/ml for 10 min;
from Molecular Probes), as previously described (Almeida et al.,
2004). Each experiment was repeated using different cell cultures in
duplicate, and cell counting was carried out in at least six fields per
coverslip, with a total of approximately 300 cells. Results are
expressed as mean±SEM and statistical significance (Pb0.05) was
evaluated by one-way ANOVA followed by Newman–Keuls
multiple comparison test.
Immunocytochemical analysis
Immunocytochemistry assays were performed as previously
described (Rebola et al., 2005a,b) after incubation with drugs, as
described for the viability assays. For the double labelling with
mitotracker-red and anti-cytochrome c antibody (Almeida et al.,
2004), the neurons were incubated for 1 h in Krebs buffer with
500 nMmitotracker-red (Molecular Probes), a mitochondrial marker
that is insensitive to the mitochondrial potential (Krohn et al., 1999).
The following steps had to be performed protected from light. After
fixation in 4% paraformaldehyde, the neurons were washed three
times with PBS, incubated for 10 min with 20 mM glycine,
permeabilized with 0.1% saponin, incubated for 30 min with a
mouse anti-cytochrome c antibody (1:100; PharMingen, San Diego,
USA) and, after washing, with an Alexa Fluor 488-labelled anti-
mouse secondary antibody (1:200; Molecular Probes). For the
immunocytochemical double labelling of MAP-2 and synaptophy-
sin, the fixed permeabilized neurons were incubated for 1 h with
rabbit anti-MAP-2 antibody (1:400; Santa Cruz Biotechnologies,
Freelab, Lisbon, Portugal) and mouse anti-synaptophysin antibody
(1:200; Sigma, Sintra, Portugal). The secondary antibodies used
were Alexa Fluor 488-labelled anti-rabbit and Alexa Fluor 594-
labelled anti-mouse antibodies (1:200; Molecular Probes).
The labelled neurons were visualized using either a fluores-
cence microscope (Zeiss Axiovert 2000, PG-HITEC, Portugal) or a
confocal microscope (MRC 600, Bio-Rad, Hercules, USA).
Immunoreactivities were evaluated using 3 representative fields
per coverslip (magnification ×600). Quantitative assessment of
synaptophysin immunoreactivity was calculated by comparison of
the total number of labelled dots in control versus test conditions(approximately one thousand dots per field, with 3 fields counted
per experimental condition). Results are expressed as mean±SEM
and statistical significance (Pb0.05) was evaluated by one-way
ANOVA followed by Newman–Keuls multiple comparison test.
Western blot analysis
Hippocampal neurons, plated on 6 wells dishes, were gently
scraped in lysis buffer (50 mM KCl, 50 mM PIPES, 10 mM
EGTA, 2 mM MgCl2, 0.5% Triton X-100, 1 mM PMSF, 1 mM
dithiothreitol and 5 μg/ml of a mixture of protease inhibitors
containing chymostatin, leupeptin, pepstatin A and antipain) and
subject to 3 freezing cycles at −80 °C. Neuronal extracts were
diluted at the final concentration of 1 μg protein/μl in SDS–PAGE
buffer and 20 μg were separated by SDS–PAGE (7.5% with a 4%
concentrating gel), as previously described (Rebola et al., 2005a).
After electro-transfer, the membranes were incubated overnight at
4 °C with mouse anti-synaptophysin antibody (1:1000) or rabbit
anti-MAP-2 antibody (1:400), washed and incubated with an
alkaline phosphatase-conjugated anti-mouse secondary antibody
(1:2000; Calbiochem, PG-HITEC). The membranes were then
analysed with a VersaDoc 3000 (Biorad) after incubation with ECF
(Amersham, Buckinghamshire, UK). The membranes were then re-
probed and tested for tubulin immunoreactivity using a mouse anti-
α-tubulin antibody (1:1000; Zymed, Lisbon, Portugal), as pre-
viously described (Rebola et al., 2005a).
Hippocampal synaptosomes
Male Wistar rats (8 weeks old, 150–160 g, obtained from
Charles River, Barcelona, Spain) were handled according to the EU
guidelines for use of experimental animals (86/609/EEC), the rats
being anesthetized under halothane atmosphere before being
sacrificed by decapitation. Membranes from Percoll-purified
hippocampal synaptosomes were prepared as previously described
(Rebola et al., 2005a). Briefly, the two hippocampi from one rat
were homogenized at 4 °C in sucrose solution (0.32 M) containing
10 mM HEPES, 1 mM EGTA and 1 mg/ml bovine serum albumin
(fatty acid-free), pH 7.4, centrifuged at 3000×g for 10 min at 4 °C;
the supernatants were collected, centrifuged at 14,000×g for
12 min at 4 °C and the pellet was resuspended in 1 ml of a 45%
(v/v) Percoll solution made up in a Krebs solution (composition:
140 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM EDTA, 5 mM
glucose, pH 7.4). After centrifugation at 14,000×g for 2 min at
4 °C, the top layer was removed (synaptosomal fraction), washed
in 1 ml Krebs solution and resuspended in Locke’s buffer (with
154 mM NaCl, 5.6 mM KCl, 5 mM HEPES, 3.6 mM NaHCO3,
2.3 mM CaCl2, 1 mM MgCl2, 5 mM glucose, pH 7.2).
The mitochondrial reduction status of the synaptosomes
(Mattson et al., 1998) was measured by a colorimetric assay for
cell survival, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT, from Sigma), as previously described
(Almeida et al., 2004). The synaptosomes (1 mg/ml) were
incubated for 2 h at 37 °C in Locke’s buffer in the absence or
presence of STS (100 nM) and/or SCH58261 (50 nM). We used a
higher concentration of STS in the experiments using synapto-
somes to compensate for the shorter exposure periods imposed by
the limited period of viability of this preparation, which does not
exceed 4 h. MTT (0.5 mg/ml) was then added and incubated for
1 h at 37 °C in the dark. As MTT is converted to a water-insoluble
blue product (formazan) by viable terminals, the precipitated dye
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synaptosomes to isopropanol containing 0.04 M HCl. Values were
expressed as the percentage of optical density of control synapto-
somes, i.e. in the absence of drugs.
Caspase-3 activity was assessed in synaptosomes using a
colorimetric pseudo-substrate of caspase-3, N-acetyl-Asp-Glu-Val-
Asp-p-nitroanilide (Ac-DEVD-pNA; Calbiochem), as previously
described for cultured neurons (Almeida et al., 2004). After
incubation for 2 h at 37 °C in Locke’s buffer in the absence or
presence of STS (100 nM) and/or SCH58261 (50 nM), the
synaptosomes were pelleted and lysed by addition of lysis buffer
before quantification of protein. The suspension (50 μg protein)
was then incubated for 2 h at 37 °C in the dark with 100 μM Ac-
DEVD-pNA in CHAPS buffer containing 25 mM HEPES–Na,
10 mM dithiothreitol, 10% (w/v) sucrose and 0.1% (w/v) CHAPS,
pH 7.4 before reading the optical density at 405 nm.Fig. 1. Blockade of A2A receptors prevents the apoptosis induced by staurosporine in
neuronal viability (A) and increased the number of apoptotic-like neurons (i.e. displ
This was prevented by the A2A receptor antagonists, SCH58261 (SCH, 50 nM) or
Results are mean±SEM from 6 independent hippocampal cultures and a total of at l
one-way ANOVA followed by Newman–Keuls test). Blockade of A2A receptors
mitochondria in cultured hippocampal neurons (C) as shown by the loss of co-local
in the displayed merged confocal images (magnification ×600). These results areDrugs and solutions
STS was purchased from Sigma and made up as a 5 mM stock
in dimethylsulfoxide before diluting into working solutions at the
desired concentration. The selective antagonists of adenosine A2A
receptors, SCH58261 (provided by S. Weiss, Vernalis, UK) or
ZM241385 (Tocris, Northpoint, UK) were prepared as 5 mM stock
solutions in dimethylsulfoxide and then dissolved (b0.001%
dimethylsulfoxide) in the working solutions. All culture media
were from GIBCO BRL (Life Technologies, Scotland, UK).
Results and discussion
In accordance with different studies confirming the ability of
the non-selective protein kinase inhibitor staurosporine to trigger
neuronal damage through an apoptotic-like process (e.g. Koh et al.,cultured hippocampal neurons. Staurosporine (STS, 30 nM, 24 h) decreased
aying a condensed nucleus simultaneously labeled with Syto-13 and PI) (B).
ZM241385 (ZM, 50 nM), that were devoid of effects in the absence of STS.
east 300 neurons per coverslip were counted. ∗Pb0.05 versus control (CTR,
also prevented STS (30 nM, 24 h)-induced release of cytochrome c from
ization of mitotracker-red (red) and cytochrome c (green) immunoreactivities
representative of 4 experiments.
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exposed to staurosporine (30 nM) displayed morphological
characteristics of neuronal apoptosis such as neuronal shrinkage,
chromatin condensation and nuclear pyknosis. At its reported EC50
concentration (30 nM, see Koh et al., 1995; Prehn et al., 1997),
staurosporine decreased the number of viable neurons (from a
control value of 84±3% to 57±2% of viable cells; Fig. 1A) and
increased the number of primary (from 0% to 6±1%) and
secondary apoptotic cells (from 15±3% to 36±2%) after 24 h of
incubation (n=6; Fig. 1B). As illustrated in Fig. 1C, STS also
triggered the loss of cytochrome c from mitochondria, a key
feature of commitment to apoptotic death in neurons (AhlemeyerFig. 2. Staurosporine (STS, 30 nM) causes a precocious synaptic degeneration,
blockade. Panel A shows that STS decreased MAP-2 (red) and synaptophysin (gree
of paired photographs from the left), 12 h (second column) or 24 h (third column) o
of A2A receptor with SCH58261 (SCH, 50 nM). Similar qualitative results were
confirmed by Western blot quantification, showing that the density of synaptic
decreased by STS (30 nM, 24 h) and this decrease is prevented by SCH58261 (50
control conditions (CTR, lack of added drugs), are mean±SEM of 3 experiments
Keuls test). Panel C shows that at the early time point evaluated (6 h), STS (30 n
neuronal viability (n=5–6).et al., 2002; Krohn et al., 1999). In 4 experiments, we observed a
33±4% decrease in the number of cell displaying a co-localization
of a mitochondrial marker (mitotracker-red) and cytochrome c
immunoreactivity.
We then tested if adenosine A2ARs directly controlled neuronal
apoptosis. For this purpose, we tested the ability of two chemically
distinct and selective antagonists of A2ARs, SCH58261 and
ZM241385, used in supra-maximal concentrations of 50 nM, to
modify STS-induced neuronal damage. As illustrated in Figs. 1A
and B, the presence of either SCH58261 or ZM241385 significantly
(Pb0.05) attenuated STS-induced neurotoxicity. Furthermore, the
presence of SCH58261 (50 nM) abrogated the STS-induced de-before overt neuronal loss occurred, which is prevented by A2A receptor
n) immunoreactivity in cultured hippocampal neurons after 6 h (first column
f incubation with STS. This was abrogated at all time points upon blockade
obtained in 4 experiments. This STS-induced synaptic degeneration was
proteins (synaptophysin and MAP-2) in cultured hippocampal neurons is
nM) (B). The results, presented as percentage of the densitometric values of
. ∗Pb0.05 compared to control (one-way ANOVA followed by Newman–
M) caused a decrease of synaptic markers without evident modification of
Fig. 3. Staurosporine (STS, 100 nM) decreased mitochondria function
(evaluated by the reduction of MTT in panel A) and induced caspase-3
activation (evaluated by the increased fluorescence of its pseudo-substrate
Ac-DEVD-pNA, panel B) in hippocampal nerve terminals (2 h of
incubation). Both effects were prevented upon blockade of A2A receptor
with SCH58261 (SCH, 50 nM). Results are mean±SEM of 8–15
experiments. ∗Pb0.05 using the paired Student's t test.
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(Fig. 1C). Overall, these results indicate that the activation of
adenosine A2ARs is an important event for the full expression of
features of apoptotic damage induced by STS in cultured
hippocampal neurons, since the blockade of A2ARs considerably
reduced STS-induced membrane leakage and prevented the STS-
induced release of cytochrome c from mitochondria.
We have previously found that A2ARs are mostly located in
synapses in forebrain neurons (Lopes et al., 2004; Rebola et al.,
2005a). This is in agreement with the neuroprotection afforded by
A2ARs since it has been suggested that the damage of neurons in
the course of neurodegenerative diseases might start with a
synaptic dysfunction that gradually evolves into an overt pattern of
neuronal degeneration (Herkenham et al., 1991; Li et al., 2001;
Selkoe, 2002). Interestingly, it has also been shown that STS is
directly toxic to nerve terminals and STS-treated nerve terminals
from the adult brain display apoptotic-like features (Gylys et al.,
2002; Mattson et al., 1998; Xie et al., 2005). Thus, we decided to
investigate if it was possible to temporally dissociate STS-induced
synaptic and whole neuronal damage, as previously done by others
using other noxious stimuli (e.g. Berliocchi et al., 2005; Cowan et
al., 2001; Ikegami and Koike, 2003; Ivins et al., 1998), and to test
if the synaptically located A2ARs might play a prominent role in
the control of the putative synaptotoxicity caused by STS.
For that purpose, we began to test if STS caused initial synaptic
alterations and a subsequent modification of neuronal viability. As
illustrated in Fig. 2A, after 6 h of exposure to 30 nM STS, there
was a reduction of synaptophysin (a presynaptic marker) and
MAP-2 (a dendritic marker) immunoreactivities (n=4). Interest-
ingly, at this time point (6 h), we found no statistical difference
(PN0.05, n=5) between the number of viable and apoptotic-like
neurons between control and STS-treated neurons whereas a 17.1±
3.1% reduction (n=4) of the number of dots labelled with
synaptophysin was observed (Fig. 2C). At a later time point (12 h),
the STS-induced decrease of synaptophysin and MAP-2 immunor-
eactivities became more evident (Fig. 2A) and neuronal damage
could now be measured (18.0±2.6% decrease of viable neurons,
n=5). Finally, at the latest tested time point (after 24 h of exposure
to STS), synaptotoxicity was also evident (37.7±1.4% decrease of
the number of synaptophysin-labelled dots, n=4 and 33.8±9.9%
and 36.3±13.8% decrease of synaptophysin and MAP-2 immu-
noreactivity evaluated by Western blot, n=3) and there was a more
evident neuronal damage (33.7±2.0% decrease of viable neurons,
n=5).
As displayed in Fig. 2, this early and sustained decrease of
labelling of synaptic markers caused by STS was abrogated when
A2ARs were blocked with SCH58261 (50 nM), which was devoid
of effects in the absence of STS (n=4–5). This indicates that
synaptic A2ARs play a prominent role in the control of early STS-
induced synaptotoxicity, in accordance with their synaptic
localization in cultured hippocampal neurons (Rebola et al.,
2005a). Since A2ARs are also enriched in nerve terminals in the
adult rat brain (Rebola et al., 2005a), we next tested if the blockade
of A2ARs might also prevent the STS-induced features of synaptic
apoptosis (see Gylys et al., 2002, Mattson et al., 1998; Xie et al.,
2005), using the only preparation that allows studying nerve
terminals independently of other brain elements, the synaptosomal
preparation (Nicholls, 2003).
As shown in Fig. 3, exposure of hippocampal synaptosomes
obtained from adult rats to STS (100 nM) for 2 h decreased MTT
reduction to 95.9±0.8% of control (n=15, Pb0.05) and increasedcaspase-3 activity by 11.5±2.3% (n=16, Pb0.05). According to
our expectation based on the results obtained with cultured
neurons, the STS-induced modifications observed in hippocampal
synaptosomes were no longer observed when they were treated
with 50 nM SCH58261 (n=12–16), which was devoid of effects
by itself (Fig. 3).
This observed precocious susceptibility of nerve terminals to
STS re-enforces the concept that synaptic toxicity might be an
initial target of insults triggering a slowly developing apoptotic
neuronal damage in the brain, such as these occurring in different
neurodegenerative diseases. In fact, synaptic dysfunction and
damage has been recognised as an early event in the course of
different neurodegenerative diseases such as Alzheimer’s (Selkoe,
2002), Parkinson’s (Herkenham et al., 1991), Huntington’s (Li et
al., 2001) or prion’s diseases (Ferrer, 2002) as well as in HIV
infection (Garden et al., 2002), schizophrenia (Glantz et al., 2006)
or motor neuropathies (Raff et al., 2002), which can be observed
before overt neuronal loss occurs. However, it still remains
debatable if this precocious synaptic degeneration can be
considered a localised synaptic apoptosis (see Mattson et al.,
1998). One consensual mechanism to explain the greater suscept-
ibility of nerve terminal to insidious brain insults is the particular
susceptibility to dysfunction of synaptic mitochondria. In fact,
mitochondria located in nerve terminals have a different morphol-
ogy and functional properties when compared to mitochondria
located in other neuronal compartments or brain cells (e.g. Battino
et al., 2000; Collins et al., 2002; Davey et al., 1998; Muller et al.,
2005). Thus, nerve terminals are at particular catastrophic risk
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metabolic demand imposed by the release of neurotransmitters
(Davey et al., 1998; Nicholls, 2003) and to the higher calcium
transients that are more poorly managed by synaptic mitochondria
(Brown et al., 2006). This mitochondria dysfunction in synapses
has the potential to trigger an apoptotic-like response, namely a
restricted activation of caspase-3 in nerve terminals (Cowan et al.,
2001; Mattson et al., 1998; Xie et al., 2005), as we also observed.
However, it is still unclear if synaptic degeneration is indeed
caused by caspase activation and it is not known what are the
mechanisms involved in this dying-back process beginning as a
synaptic degeneration and later evolving into overt neuronal loss
(reviewed in Luo and O’Leary, 2005; Raff et al., 2002). In fact,
some studies reported that inhibition of caspase-3 prevents the
early synaptic damage (Cowan et al., 2001; Ivins et al., 1998;
Mattson et al., 1998; Xie et al., 2005) and the antidromic
propagation of activated caspases is associated with neuronal
apoptosis (Cowan et al., 2001), whereas other elegant studies
found that the inhibition of caspase-3 fails to affect the early
synaptic damage, albeit it prevents the subsequent neuronal
apoptotic death (Berliocchi et al., 2005; Finn et al., 2000; Ikegami
and Koike, 2003). The elucidation of these mechanisms of
precocious synaptic degeneration and dying-back process in
neurons would certainly bolster the possibility of controlling this
apparently reversible synaptic dysfunction which is now recog-
nised as an effective strategy to arrest neurodegenerative diseases
at their early stages before they evolve into overt irreversible
neuronal loss (Coleman and Perry, 2002).
We now found that the blockade of the synaptically located
adenosine A2ARs might achieve this goal. In fact, blockade of
A2ARs was effective to directly prevent the STS-induced
mitochondria dysfunction in purified nerve terminals and also
abrogated the initial STS-induced synapto-toxicity and later
apoptotic-like neuronal damage in cultured hippocampal neurons.
This is in agreement with in vivo studies showing that the
blockade of these synaptically located A2ARs (Lopes et al., 2004;
Rebola et al., 2005a) prevented the initial synapto-toxicity caused
by chronic noxious brain insults such as in animal models of
Parkinson’s disease (Chen et al., 2001; Ikeda et al., 2002) or
restraint stress (Cunha et al., 2006). Furthermore, the current
observation that A2AR blockade directly prevents neuronal
apoptosis caused by STS provides a mechanistic basis for the
ability of A2AR antagonists to prevent neurotoxicity and/or
phenotypic burden in animal models of different neurodegenera-
tive diseases known to involve apoptotic features such as
Parkinson’s (Chen et al., 2001; Ikeda et al., 2002), Alzheimer’s
(Dall’Igna et al., 2007) or Huntington’s disease (Blum et al.,
2003).
However, it still remains to be defined what are the mechanisms
associated with this ability of A2ARs to control neuronal apoptosis.
A2ARs are classically defined as G protein-coupled receptors
selectively activating GαS- (or Gαolf-) containing proteins and their
main transducing system is assumed to be the increase of cAMP
levels (Fredholm et al., 2005). Increased cAMP levels effectively
counteract STS-induced neuronal apoptosis (Goswami et al., 1998;
Park and Cho, 2006). However, we now report that it is the
blockade of A2ARs (expected to limit cAMP accumulation) which
affords protection against STS-induced damage. This makes it
unlikely that the A2AR neuroprotection might involve the cAMP
transducing system. Accordingly, several reports have provided
evidence supporting the possible coupling of A2ARs with othertransducing systems (reviewed in Fredholm et al., 2005). Thus,
A2ARs might control protein phosphatases (Murphy et al., 2003;
Revan et al., 1996), which is of particular relevance since
phosphatase activities play a prominent role in the control of
mitochondria function and neuronal viability after noxious stimuli
(Agostinho and Oliveira, 2003; Almeida et al., 2004). Another
pathway potentially relevant to understand the neuroprotection
afforded by A2AR blockade is the control by A2ARs of MAPKs
(Schulte and Fredholm, 2003; Seidel et al., 1999), which is
independent of the cAMP pathway (Gsandtner et al., 2005; Klinger
et al., 2002; Sexl et al., 1997), and is known to control the
susceptibility of brain tissue to damage (Wang et al., 2004).
Accordingly, it was recently proposed that the control by A2ARs of
the ischemia-induced brain damage was related the ability of A2AR
antagonists to blunt the ischemia-induced accumulation of
phosphorylated forms of p38 (Melani et al., 2006). However, the
elucidation of the mechanism by which A2ARs control neuronal
apoptosis might only be achieved after establishing the transducing
systems operated by A2ARs in neurons, an issue that largely
remains undefined.
In conclusion, we now report that A2AR antagonists prevent
STS-induced apoptosis, which provide a rationale to understand
the ability of A2AR antagonists to prevent the extent of neuronal
damage caused by noxious brain stimuli (reviewed in Cunha,
2005).
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